In both domestic and international industrial contexts, pharmaceutical manufacturing is a strategically important sector. It ensures the continuous supply of high-quality medicines to patients, plays a central role in research, development, and innovation, and significantly contributes to national economic performance. For these reasons, it is essential that companies in this sector continuously modernize and develop.
With the support of European Union funding, ExtractumPharma Zrt. carried out a capacity expansion and technological upgrade at its facility in Kunfehértó.
| ExtractumPharma Zrt. was founded in 1993 as a Hungarian-owned pharmaceutical company to meet domestic medicine needs. Between 1993 and 1995, the company acquired manufacturing rights for established products and built its initial portfolio. From 1995 to 2000, it strengthened its presence in the domestic market and launched a contract manufacturing division. Between 2000 and 2010, the company continuously developed its infrastructure and products, acquiring licensed medicines, producing new generic formulations, and beginning export activities. From 2011 to 2021, the focus shifted to strengthening R&D activities and registering products for export markets, alongside an expansion of production capacity. |
As part of the EU-funded project, the company installed several state-of-the-art manufacturing devices that meet European Union standards. The new production line significantly increases the speed and reliability of film-coated tablet packaging. It enables a higher-capacity, more efficient coating process while reducing raw material and energy consumption. Additionally, a newly installed homogenizer ensures uniform mixing of powdered raw materials for direct-compression manufacturing. These devices were integrated immediately into the company’s daily operations.
Thanks to this investment, ExtractumPharma Zrt. has substantially increased its production capacity and modernized its manufacturing technology. The production processes are now more flexible and cost-effective, while the products fully comply with European quality standards. As a result, the company has strengthened its competitiveness both domestically and internationally and can ensure the continuous, reliable supply of medicines over the long term.
The development was implemented from EU funding in the project GINOP-1.2.1-16-2017-00076 under the Economic Development and Innovation Operational Programme Plus.
Find out more about the project in the Project Finder:Details
